Clinical Trial Update: Study of Methylphenidate to Treat Gait Disorders And Attention Deficit In Parkinson's Disease (PARKGAIT-II) [Phase 4]

View source ↗

Summary

Phase 4 PARKGAIT-II trial assessing methylphenidate for gait disturbances and attention deficits in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia
• Gait Disorders
• Parkinson Disease

Drugs mentioned

• Methylphenidate (Methylphenidate)

Snippet

Sponsor: University Hospital, Lille | Conditions: Parkinson's Disease, Gait Disorders, Neurologic | Phase 4 | Status: COMPLETED